| |
| Join us virtually during AAPS PharmSci360 |
|
|
|
|
|
| At Catalent, we have the passion to unlock the potential of your small and large molecules.
Attend our partner presentations and learn data driven strategies to accelerate your molecule development. Discover Catalent’s OptiDose™ Design Solution, a structured approach to dose form design to develop better treatments that address patient needs.
Don’t miss our scientific research poster that will be presented virtually: Lipid-based Formulation Development of Poorly Soluble Drug for Fast Access to Animal and Human PK Proof of Concept.
Discover more about the latest technologies and best practices in drug development. |
|
|
| | |
|
|
| |
| Join Catalent Experts at our Partner Presentations |
|
|
|
|
|
| |
| WEEK 1 - PARTNER PRESENTATION |
|
|
|
|
|
| Title: Data-Driven Strategies to Accelerate Your Molecule’s Development Path Date: Monday, October 26, 2020 Time: 2pm to 3pm ET
Lisa Caralli Director of Science and Technology, Pharmaceutics Catalent
Catalent expert Lisa Caralli will introduce a fast and efficient development process that can help deliver the right clinical candidate, best formulation strategy and an optimal dosage form to Phase 1. The presentation will discuss in detail data-driven approaches including PBPK modeling, parallel formulation screening, API sparing techniques and optimal early dosing strategies that will help avoid development pitfalls and de-risk path to clinic. |
|
|
| | |
|
|
| WEEK 2 - PARTNER PRESENTATION |
|
|
|
|
|
| Title: Patient-Focused Drug Design: A Structured Approach to Dose Form design to develop better treatments that address patient needs Date: Wednesday, November 4, 2020 Time: 9:00AM – 10:00AM ET
Cornell Stamoran, Ph.D. Vice President of Corporate Strategy Catalent |
|
|
| | |
|
|
| William Chin, Ph.D. Manager, Global Scientific Affairs Catalent
Catalent experts Cornell Stamoran, Ph.D. and William Chin, Ph.D. will present the OptiDose™ Design Solution a comprehensive early dose form assessment and a strategic development assessment tool to help drive the dose design decision process. This design driven approach combines a scientific data-driven tool with Catalent’s comprehensive assessment and development expertise to craft the ideal dose form to optimize your molecule’s potential to create better treatments and launch successful patient-focused products to market faster. |
|
|
| | |
|
|
| |
| |
| Catalent Values Your Insight | | We’d love to hear from you in a brief survey. Marketview Research, an independent research firm, is collecting date on our behalf in this confidential survey about the future of our industry and steps we can take to deliver better treatments to patients.
The first 250 qualifying participants will each receive a $10 e-gift card. All qualifying participants who complete the survey will be entered into a drawing to win one of ten (10) $250 e-gift cards. We appreciate your feedback. |
|
|
|
|
|
| |
| Every molecule has a challenge. We have a solution. | | | | or call +1 877 891 9609 to speak with one of our experts today! | | |
|
|
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here. For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
|
| |
